Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet’s disease

Habibagahi, Zahra; Habibagahi, Mojtaba; Heidari, Masoomeh

doi:10.3109/s10165-009-0246-1

Cited by 27 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ustekinumab is a humanized monoclonal antibody against interleukin 12 (IL‐12) and IL‐23 . IL‐23 is critical for the differentiation of Th17 lymphocytes, and previous studies have demonstrated the key role of Th1 and Th17 in the pathogenesis of BD and the correlation of these cytokines with disease activity . Genome‐wide association studies conducted in Japan and Turkey showed IL23R and IL12RB2 loci variations to be associated with BD .…”

Section: Introductionmentioning

confidence: 99%

Long‐Term Outcome of Ustekinumab Therapy for Behçet's Disease

Mirouse

Barète

Desbois

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. Oral ulcers, the hallmark lesion of Behçet's disease (BD), can be disabling and resistant to conventional treatment, and there is a need for safe and effective treatment. We undertook this study to investigate the long-term safety and efficacy of ustekinumab therapy for BD-related oral ulcers that are resistant to colchicine.Methods. This multicenter, prospective, open-label study included 30 patients who fulfilled the criteria of the International Study Group for BD and who were diagnosed as having active oral ulcers resistant to colchicine. Patients were treated subcutaneously with ustekinumab 90 mg at inclusion, at week 4, and then once every 12 weeks. Each patient was assessed longitudinally for the presence and number of oral ulcers, and median numbers of oral ulcers (with interquartile range [IQR]) were calculated. The primary efficacy end point was the proportion of patients at week 12 who experienced complete response, defined as having no oral ulcers.Results. The median number of oral ulcers per patient during ustekinumab therapy was significantly lower at week 12 compared to baseline (0 [IQR 0-1] versus 2 [IQR 2-3]; P < 0.0001). Complete response was achieved in 60.0% and 88.9% of patients at weeks 12 and 24, respectively. The median Behçet's Syndrome Activity Score (in which higher scores indicate more active disease) was significantly lower at weeks 12 and 24 (17.5 [IQR 10-42.5] and 10 [IQR 8-11], respectively) versus baseline (70 [IQR 50-70]; P < 0.0001). After a median follow-up of 12 months (IQR 6-16 months), 26 patients (86.7%) were still receiving ustekinumab treatment. Reasons for ustekinumab discontinuation included BD flare (n = 3) and side effects (n = 1). Seven patients (23.3%) experienced adverse events, including headaches (n = 4) and asthenia (n = 2), with no serious side effects.Conclusion. Ustekinumab seems to be effective in treating BD-related oral ulcers that are resistant to treatment with colchicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Long‐Term Outcome of Ustekinumab Therapy for Behçet's Disease

Mirouse

Barète

Desbois

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…Although the use of the ELISA kit was different from the method used in the previous study , the serum soluble VE‐cadherin levels in the present control subjects were higher than those in the previous study. Outside of sepsis patients, elevated circulating levels of VE‐cadherin have been found in patients with coronary atherosclerosis , cancers , ovarian hyperstimulation syndrome , and Behçet's disease . Among controls in the present study, no patient had ovarian hyperstimulation syndrome, cancers or rheumatic diseases, but it was possible that patients with asymptomatic coronary atherosclerosis could not be fully excluded.…”

Section: Discussionmentioning

confidence: 57%

Soluble Vascular Endothelial‐Cadherin Levels in Patients With Sepsis Treated With Direct Hemoperfusion With a Polymyxin B‐immobilized Fiber Column

et al. 2014

View full text Add to dashboard Cite

Capillary permeability is a tightly regulated feature of microcirculation in all organ beds; however, in sepsis this feature is fundamentally altered. Several molecules are investigated as associated factors with capillary permeability and vascular endothelial (VE)-cadherin internalization by vascular endothelial growth factor (VEGF)-induced signaling through VEGF receptors leads to increased vascular endothelial cell detachment and trans-endothelial permeability. We investigated serum soluble VE-cadherin levels in septic patients. An enzyme-linked immunoassay was used to measure serum soluble VE-cadherin levels in 47 septic patients treated by direct hemoperfusion with a polymyxin B-immobilized fiber column (DHP-PMX). The serum soluble VE-cadherin level of septic patients before PMX-DHP was 3424.1 ± 2033.0 ng/mL, which was significantly lower than that of the controls (5862.0 ± 1521.2 ng/mL; P < 0.0001). The time course of serum soluble VE-cadherin levels remained unchanged during PMX-DHP therapy. There was no significant difference in serum soluble VE-cadherin levels before PMX-DHP therapy between survivors and non-survivors, and there was no significant difference in those levels between the groups at any time after the initiation of PMX-DHP therapy. There was no correlation between soluble VE-cadherin levels and clinical data, except white blood cell count (r = -0.277, P = 0.0009). There was no correlation between soluble VE-cadherin levels and the levels of angiopoietin 1 and 2. In summary, the relationship between VE-cadherin and capillary permeability in sepsis could not be demonstrated. Soluble VE-cadherins are not reflected in the balance between intercellular junction plasticity and integrity, but VE-cadherin stabilization by its phosphorylation or internalization may be associated with capillary permeability.

show abstract

“…A previous study has shown higher IL-23 in sera of BD patients with uveitis and found that there was a meaningful correlation between IL-23 content and disease activity [3]. Moreover, Lew et al reported an increased expression of IL-23 p19 mRNA in erythema nodosum-like lesions of BD patients [4].…”

mentioning

confidence: 97%